Literature DB >> 20543575

A20 inhibition of NFκB and inflammation: targeting E2:E3 ubiquitin enzyme complexes.

Noula Shembade, Edward Harhaj.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20543575      PMCID： PMC3052412          DOI： 10.4161/cc.9.13.12269

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  11 in total

1.  Structural basis for ubiquitin recognition and autoubiquitination by Rabex-5.

Authors:  Sangho Lee; Yien Che Tsai; Rafael Mattera; William J Smith; Michael S Kostelansky; Allan M Weissman; Juan S Bonifacino; James H Hurley
Journal:  Nat Struct Mol Biol       Date:  2006-02-05       Impact factor: 15.369

2.  The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20.

Authors:  Noula Shembade; Nicole S Harhaj; Kislay Parvatiyar; Neal G Copeland; Nancy A Jenkins; Lydia E Matesic; Edward W Harhaj
Journal:  Nat Immunol       Date:  2008-02-03       Impact factor: 25.606

Review 3.  A20: central gatekeeper in inflammation and immunity.

Authors:  Beatrice Coornaert; Isabelle Carpentier; Rudi Beyaert
Journal:  J Biol Chem       Date:  2008-11-13       Impact factor: 5.157

4.  Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice.

Authors:  E G Lee; D L Boone; S Chai; S L Libby; M Chien; J P Lodolce; A Ma
Journal:  Science       Date:  2000-09-29       Impact factor: 47.728

5.  De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling.

Authors:  Ingrid E Wertz; Karen M O'Rourke; Honglin Zhou; Michael Eby; L Aravind; Somasekar Seshagiri; Ping Wu; Christian Wiesmann; Rohan Baker; David L Boone; Averil Ma; Eugene V Koonin; Vishva M Dixit
Journal:  Nature       Date:  2004-07-18       Impact factor: 49.962

6.  Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20.

Authors:  Su-Chang Lin; Jee Y Chung; Betty Lamothe; Kanagalaghatta Rajashankar; Miao Lu; Yu-Chih Lo; Amy Y Lam; Bryant G Darnay; Hao Wu
Journal:  J Mol Biol       Date:  2007-12-04       Impact factor: 5.469

7.  The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling.

Authors:  Noula Shembade; Kislay Parvatiyar; Nicole S Harhaj; Edward W Harhaj
Journal:  EMBO J       Date:  2009-01-08       Impact factor: 11.598

8.  The human T-cell leukemia virus type 1 Tax oncoprotein requires the ubiquitin-conjugating enzyme Ubc13 for NF-kappaB activation.

Authors:  Noula Shembade; Nicole S Harhaj; Masahiro Yamamoto; Shizuo Akira; Edward W Harhaj
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

9.  Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity.

Authors:  Paul C Evans; Huib Ovaa; Maureen Hamon; Peter J Kilshaw; Svetlana Hamm; Stefan Bauer; Hidde L Ploegh; Trevor S Smith
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

10.  Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

Authors:  Mara Compagno; Wei Keat Lim; Adina Grunn; Subhadra V Nandula; Manisha Brahmachary; Qiong Shen; Francesco Bertoni; Maurilio Ponzoni; Marta Scandurra; Andrea Califano; Govind Bhagat; Amy Chadburn; Riccardo Dalla-Favera; Laura Pasqualucci
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962
View more
  16 in total

1.  RNF11 modulates microglia activation through NF-κB signalling cascade.

Authors:  Nirjari V Dalal; Elaine L Pranski; Malu G Tansey; James J Lah; Allan I Levey; Ranjita S Betarbet
Journal:  Neurosci Lett       Date:  2012-09-11       Impact factor: 3.046

2.  The kinase IKKα inhibits activation of the transcription factor NF-κB by phosphorylating the regulatory molecule TAX1BP1.

Authors:  Noula Shembade; Rajeshree Pujari; Nicole S Harhaj; Derek W Abbott; Edward W Harhaj
Journal:  Nat Immunol       Date:  2011-07-17       Impact factor: 25.606

3.  Linear polyubiquitin chains: a new modifier involved in NFκB activation and chronic inflammation, including dermatitis.

Authors:  Kazuhiro Iwai
Journal:  Cell Cycle       Date:  2011-09-15       Impact factor: 4.534

4.  Immune regulator LGP2 targets Ubc13/UBE2N to mediate widespread interference with K63 polyubiquitination and NF-κB activation.

Authors:  Jessica J Lenoir; Jean-Patrick Parisien; Curt M Horvath
Journal:  Cell Rep       Date:  2021-12-28       Impact factor: 9.423

5.  E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs.

Authors:  Enguang Bi; Rong Li; Laura C Bover; Haiyan Li; Pan Su; Xingzhe Ma; Chunjian Huang; Qiang Wang; Lintao Liu; Maojie Yang; Zhijuan Lin; Jianfei Qian; Weijun Fu; Yong-Jun Liu; Qing Yi
Journal:  J Clin Invest       Date:  2018-10-02       Impact factor: 14.808

Review 6.  TGF-β signaling pathway mediated by deubiquitinating enzymes.

Authors:  Soo-Yeon Kim; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2018-10-22       Impact factor: 9.261

Review 7.  A20-mediated negative regulation of canonical NF-κB signaling pathway.

Authors:  Rajeshree Pujari; Richard Hunte; Wasif N Khan; Noula Shembade
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

8.  Neuronal RING finger protein 11 (RNF11) regulates canonical NF-κB signaling.

Authors:  Elaine L Pranski; Nirjari V Dalal; Jeremy H Herskowitz; Adam L Orr; Leah A Roesch; Jason J Fritz; Craig Heilman; James J Lah; Allan I Levey; Ranjita S Betarbet
Journal:  J Neuroinflammation       Date:  2012-04-16       Impact factor: 8.322

9.  Human T-cell leukemia virus type 1 (HTLV-1) tax requires CADM1/TSLC1 for inactivation of the NF-κB inhibitor A20 and constitutive NF-κB signaling.

Authors:  Rajeshree Pujari; Richard Hunte; Remy Thomas; Louise van der Weyden; Dan Rauch; Lee Ratner; Jennifer K Nyborg; Juan Carlos Ramos; Yoshimi Takai; Noula Shembade
Journal:  PLoS Pathog       Date:  2015-03-16       Impact factor: 6.823

10.  The role of A20 in the pathogenesis of lymphocytic malignancy.

Authors:  Fan Zhang; Lijiang Yang; Yangqiu Li
Journal:  Cancer Cell Int       Date:  2012-11-07       Impact factor: 5.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.